for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tonix Pharmaceuticals Holding Corp

TNXP.OQ

Latest Trade

0.46USD

Change

-0.00(-0.60%)

Volume

21,149

Today's Range

0.45

 - 

0.46

52 Week Range

0.37

 - 

9.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.46
Open
0.45
Volume
21,149
3M AVG Volume
12.92
Today's High
0.46
Today's Low
0.45
52 Week High
9.88
52 Week Low
0.37
Shares Out (MIL)
15.72
Market Cap (MIL)
7.31
Forward P/E
-0.16
Dividend (Yield %)
--

Next Event

Tonix Pharmaceuticals Holding Corp at Ladenburg Thalmann Healthcare Conference

Latest Developments

More

Tonix Pharma Agreed To Pay Columbia Single-Digit Royalties On Net Sales Of Products Sold By Tonix Or Sublicensee

Tonix Pharmaceuticals Holding Corp Files Prospectus Covers Offer, Sale Of Up To 5 Million Shares Of Co's Common Stock By Lincoln Park Capital Fund, LLC

Tonix Pharmaceuticals Expands Preclinical Pipeline For Treatment Of PTSD

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).

Industry

Biotechnology & Drugs

Contact Info

509 Madison Ave Rm 306

+1.212.9809155

https://www.tonixpharma.com/

Executive Leadership

Seth Lederman

Chairman of the Board, President, Chief Executive Officer

Bradley Saenger

Chief Financial Officer, Treasurer

Jessica Edgar Morris

Chief Operating Officer

Gregory M. Sullivan

Secretary, Chief Medical Officer

John B. Rhodes

Lead Independent Director

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-154.100

2017

-31.700

2018

-26.810

2019(E)

-2.907
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.23
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-174.56
Return on Equity (TTM)
-150.71

Latest News

BRIEF-Tonix Pharmaceuticals Holding Corp Enters Into Sales Agreement With Cowen And Co

* TONIX PHARMACEUTICALS HOLDING CORP SAYS ON MAY 1, CO ENTERED INTO SALES AGREEMENT WITH COWEN AND CO RELATING TO SHARES OF CO'S COMMON STOCK OFFERED

BRIEF-Tonix Pharmaceuticals Posts Q1 Loss Of $0.88 Per Share

* TONIX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

BRIEF-Tonix Pharmaceuticals Holding Qtrly Net Loss Per Common Share $0.88

* TONIX PHARMACEUTICALS HOLDING CORP QTRLY NET LOSS PER COMMON SHARE $0.88 Source text: (https://bit.ly/2G8HkXY) Further company coverage:

BRIEF-Tonix Pharmaceuticals Holding Says Files For Mixed Shelf Of Up To $75 Mln

* TONIX PHARMACEUTICALS HOLDING SAYS FILES FOR MIXED SHELF OF UP TO $75 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KqLRZ4) Further company coverage:

BRIEF-Tonix Pharmaceuticals Receives IND Clearance By U.S. FDA For TNX-102 SL

* TONIX PHARMACEUTICALS RECEIVES IND CLEARANCE BY U.S. FDA FOR TNX-102 SL IN AGITATION IN ALZHEIMER’S DISEASE Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data

* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD

BRIEF-Tonix Pharma Reports Q4 Loss Per Share $0.71

* TONIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

BRIEF-Baker Bros Advisors LP Reports 8.9 Pct Passive Stake In Tonix Pharmaceuticals Holding As Of Dec 31, 2017 - SEC Filing

* BAKER BROS ADVISORS LP REPORTS 8.9 PERCENT PASSIVE STAKE IN TONIX PHARMACEUTICALS HOLDING AS OF DEC 31, 2017 - SEC FILING Source text: (http://bit.ly/2HcDj6B) Further company coverage:

BRIEF-Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya

* TONIX PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FOR NEW U.S. PATENT FOR THE ACTIVE INGREDIENT IN TONMYA (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals Appoints Jessica Morris As CEO

* TONIX PHARMACEUTICALS APPOINTS JESSICA MORRIS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals Completes Positive Pre-Ind Meeting With FDA For TNX-102 SL

* TONIX PHARMACEUTICALS COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL (CYCLOBENZAPRINE HCI SUBLINGUAL TABLETS) AS A CLINICAL CANDIDATE FOR AGITATION IN ALZHEIMER’S DISEASE

BRIEF-Tonix Pharmaceuticals Q3 loss per share $0.77

* Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update

BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya

* Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD

BRIEF-Tonix Pharmaceuticals enters into purchase agreement, registration rights agreement with Lincoln Park Capital Fund

* On Sept. 28 co entered into purchase agreement, registration rights agreement with Lincoln Park Capital Fund LLC

BRIEF-Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya

* Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya® (cyclobenzaprine hcl sublingual tablets) Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors

* Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals presents additional phase 2 clinical results, ongoing phase 3 trial design of Tonmya at 2017 Military Health System Research Symposium

* Tonix Pharmaceuticals presented additional phase 2 clinical results in military-related PTSD and design of ongoing phase 3 trial at the 2017 Military Health System Research Symposium

BRIEF-Tonix Pharmaceuticals to present at Military Health System Research Symposium

* Tonix Pharmaceuticals to present additional phase 2 clinical results and design of ongoing phase 3 trial in military-related ptsd at the 2017 military health system research symposium Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals Holding reports Q2 loss per share $0.65

* Tonix Pharmaceuticals reports second quarter 2017 financial results and provides programs update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up